PFIZER INC Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 12 rows in 2016. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2016-12-07: Reporting owner MACKENZIE ALEXANDER R; Form 4; Security Employee Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2016-11-04: Reporting owner BOURLA ALBERT; Form 4; Security Employee Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2016-06-30: Reporting owner MACKENZIE ALEXANDER R; Form 3; Security Employee Stock Option (right to buy); Transaction Holding.
- 2016-05-26: Reporting owner DAMELIO FRANK A; Form 4; Security Employee Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
PFE insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2016-12-07 | MACKENZIE ALEXANDER R Officer (Executive Vice President) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −30,000 0 owned after | $25.87 exercise price | $29.59 | 2016-12-08 |
| 2016-11-04 | BOURLA ALBERT Officer (Group President) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 0 owned after | $24.99 exercise price | $28.46 | 2016-11-07 |
| 2016-06-30 holding as of filing | MACKENZIE ALEXANDER R Officer (Executive Vice President) | 3 | Employee Stock Option (right to buy) Derivative · Direct | Holding | $25.87 exercise price | 2016-06-30 | ||
| 2016-05-26 | DAMELIO FRANK A Officer (Executive Vice President) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −100,000 0 owned after | $24.43 exercise price | $32.67 | 2016-05-27 |
| 2016-05-24 | CANGIALOSI LORETTA V Officer (Sr. Vice President, Controller) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −86,000 0 owned after | $25.87 exercise price | $32.35 | 2016-05-26 |
| 2016-05-10 | YOUNG JOHN D Officer (Group President) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −41,700 0 owned after | $25.87 exercise price | $32.07 | 2016-05-11 |
| 2016-05-10 | DAMELIO FRANK A Officer (Executive Vice President) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −192,000 100,000 owned after | $24.43 exercise price | $32.07 | 2016-05-11 |
| 2016-05-09 | READ IAN C Director, Officer (Chairman & CEO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −250,000 0 owned after | $25.87 exercise price | $32.09 | 2016-05-11 |
| 2016-05-09 | READ IAN C Director, Officer (Chairman & CEO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 0 owned after | $24.43 exercise price | $32.09 | 2016-05-11 |
| 2016-05-09 | SUSMAN SALLY Officer (Executive Vice President) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,884 0 owned after | $22.28 exercise price | $32.09 | 2016-05-11 |
| 2016-05-05 | SUSMAN SALLY Officer (Executive Vice President) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −56,016 23,884 owned after | $22.28 exercise price | $31.85 | 2016-05-06 |
| 2016-05-04 | SUSMAN SALLY Officer (Executive Vice President) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,100 79,900 owned after | $22.28 exercise price | $31.69 | 2016-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |